Pd-1 blockade and cdk4/6 inhibition augment nonoverlapping features of t cell activation in cancer

HIGHLIGHTS

• who: BRIEF DEFINITIVE REPORT et al. from the (UNIVERSITY) have published the Article: PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer, in the Journal: (JOURNAL) of 03/02/2023
• what: The authors demonstrate by single-cell RNA-sequencing (scRNA-seq) of patient blood and tumor samples that dual treatment does affect distinct aspects of T_cell activation, with PD-1 blockade invigorating short-term effector responses while CDK4/6 inhibition promotes the expression of markers of stemness and memory. Prior to this study, attempts at dual immunotherapy with . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.